Avivomed, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Avivomed, Inc. - overview
Established
2020
Location
Minneapolis, MN, US
Primary Industry
Healthcare
About
Based in Minneapolis, US, and founded in 2020, Avivomed, Inc. is a healthcare company, that focuses on the development of neuromodulation technology platforms to treat patients suffering from chronic conditions. In December 2021, the firm raised USD 32 million in series A funding, and it is being led by its co-founder and CEO, Steve Masson. The company also operates in Ireland.
Avivomed, Inc. ’s team of engineers and product developers engages in the research and development of implantable medical devices that are used to alter or regulate nerve activity by delivering electrical or pharmaceutical substances directly to the target location. The company's novel neuromodulation therapy is designed to address unmet therapeutic requirements that affect huge patient populations. The company plans to deploy the funds to accelerate its product development and commercialization operations.
Current Investors
Treo Ventures
Primary Industry
Healthcare
Sub Industries
Biotechnology, Healthcare, Medical Devices & Equipment
Website
http://www.avivomed.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.